Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase (PARP), dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor (EGFR). These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase I/II trial results for aldoxorubicin; topline Phase II trial results for motixafortide; topline Phase III trial results for EndoTAG-1, CPI-613, ERY-ASP, pamrevlumab, and Onivyde; and an expected patent expiration for Abraxane.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 1.8%, and the average probability a drug advances from Phase III is 13.3%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 107 trials.
- Bristol My
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Ablation or embolization
10 Radiation therapy
10 Chemotherapy
10 Targeted therapy
11 Immunotherapy
11 Drugs used specifically for the treatment of PNETs
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
34 RECENT EVENTS AND ANALYST OPINION
34 Relacorilant for Pancreatic Cancer (June 22, 2021)
35 GV1001 for Pancreatic Cancer (June 6, 2021)
36 Motixafortide for Pancreatic Cancer (December 16, 2020)
38 Masitinib for Pancreatic Cancer (December 4, 2020)
41 KEY UPCOMING EVENTS
42 PROBABILITY OF SUCCESS
43 LICENSING AND ASSET ACQUISITION DEALS
43 China CSPC Subsidiary Out-Licenses Oncology Candidate To Flame Biosciences
43 Chinese Cell Developers To Jointly Develop Solid Tumor Therapies
43 Processa Licenses Global Rights For RX-3117 From Ocuphire
43 Laevoroc Oncology Acquires Worldwide Patents For LR06
44 Lantern Pharma Enters Research And Development Collaboration with Actuate Therapeutics
44 CytoImmune Acquires City Of Hope Cell Therapy IP
44 University of Texas MD Anderson Cancer Center Unveils Collaboration With TriSalus Life Sciences
44 MD Anderson Inks New Cancer Collaboration With Mirati, Orionis
44 Qilu Obtains Greater China Rights To Cend’s Cancer Candidate
45 Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
45 NantKwest/ImmunityBio To Merge In All-Stock Deal
45 Dong-A, Jiangsu Hengrui Ink Next-Generation IO License Deal
46 Cytocom Goes Public Via Merger With Cleveland BioLabs
46 Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
46 TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
48 REVENUE OPPORTUNITY
51 CLINICAL TRIAL LANDSCAPE
52 Sponsors by status
53 Sponsors by phase
54 Recent events
57 BIBLIOGRAPHY
58 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
18 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
18 Figure 3: Pipeline drugs for pancreatic cancer, by company
19 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
19 Figure 5: Pipeline drugs for pancreatic cancer, by classification
35 Figure 6: Relacorilant for Pancreatic Cancer (June 22, 2021): Phase III – RELIANT (w/Nab-Paclitaxel)
38 Figure 7: Motixafortide for Pancreatic Cancer (December 16, 2020): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
40 Figure 8: Masitinib for Pancreatic Cancer (December 4, 2020): Phase III – AB12005
41 Figure 9: Key upcoming events in pancreatic cancer
42 Figure 10: Probability of success in the pancreatic cancer pipeline
51 Figure 11: Clinical trials in pancreatic cancer
51 Figure 12: Top 10 drugs for clinical trials in pancreatic cancer
52 Figure 13: Top 10 companies for clinical trials in pancreatic cancer
52 Figure 14: Trial locations in pancreatic cancer
53 Figure 15: Pancreatic cancer trials status
54 Figure 16: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of pancreatic cancer, 2019–28
16 Table 2: Marketed drugs for pancreatic cancer
20 Table 3: Pipeline drugs for pancreatic cancer in the US
34 Table 4: Relacorilant for Pancreatic Cancer (June 22, 2021)
36 Table 5: GV1001 for Pancreatic Cancer (June 6, 2021)
37 Table 6: Motixafortide for Pancreatic Cancer (December 16, 2020)
39 Table 7: Masitinib for Pancreatic Cancer (December 4, 2020)
49 Table 8: Historical global sales, by drug ($m), 2016–20
50 Table 9: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD) 
Sign up to the